Study summary · research use only
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this mouse study, the authors evaluated the melanocortin-derived tripeptide alpha-MSH(11-13) (KPV) in two inflammatory bowel disease models: dextran sodium sulfate (DSS) colitis and CD45RB(hi) transfer colitis. Mice with a nonfunctional melanocortin-1 receptor (MC1Re/e) also received DSS and KPV. Inflammation was monitored by weight loss, colon histology, and myeloperoxidase (MPO) activity. The abstract reports that KPV led to earlier recovery and stronger regain of body weight in DSS colitis, with significantly reduced inflammatory infiltrates and reduced colonic MPO activity. In transfer colitis, KPV was associated with recovery, weight regain, and reduced inflammatory changes. In MC1Re/e mice, KPV was reported to rescue all treated animals from death during DSS colitis. The authors conclude KPV showed anti-inflammatory action in two murine colitis models, seemingly at least partly independent of MC1R signaling.
Abstract
Despite some progress in recent years, the options for treating inflammatory bowel disease (IBD) are still dissatisfying, and surgery rates are still high. The anti-inflammatory effects of melanocortin peptides such as alpha-melanocyte-stimulating hormone (alpha-MSH) have been described recently in, for example, dextran sodium sulfate (DSS) colitis in mice. The aim of this study was to investigate the therapeutic potential of the melanocortin-derived tripeptide alpha-MSH(11-13) (KPV) and its mode of action in 2 models of intestinal inflammation. The anti-inflammatory activity of KPV was analyzed in 2 well-described models of IBD: DSS colitis, and CD45RB(hi) transfer colitis. Furthermore, animals expressing a nonfunctional melanocortin-1 receptor (MC1Re/e) received DSS for induction of colitis and were treated with KPV. The course of inflammation was monitored by weight loss and histological changes in the colon as well as by myeloperoxidase (MPO) activity. In the DSS-colitis model, treatment with KPV led to earlier recovery and significantly stronger regain of body weight. Histologically, inflammatory infiltrates were significantly reduced in KPV-treated mice, which was confirmed by the significant reduction of MPO activity in colonic tissue after KPV treatment. Supporting these findings, KPV treatment of transfer colitis led to recovery, regain of body weight, and reduced inflammatory changes histologically. In MC1Re/e mice, KPV treatment rescued all animals in the treatment group from death during DSS colitis. The melanocortin-derived tripeptide KPV showed significant anti-inflammatory effects in 2 murine models of colitis. These effects seem to be at least partially independent of MC1R signaling. In conclusion, our data suggest KPV as an interesting therapeutic option for the treatment of IBD.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.